Welcome to our dedicated page for Turnstone Biologics news (Ticker: TSBX), a resource for investors and traders seeking the latest updates and insights on Turnstone Biologics stock.
Turnstone Biologics Corp. reported developments for a biotechnology company historically focused on Selected tumor-infiltrating lymphocyte therapy for solid tumors. Company news covered TIDAL-01 clinical and preclinical data, presentations at Society for Immunotherapy of Cancer meetings, quarterly financial results, pipeline prioritization, cost-containment measures, workforce restructuring, and Nasdaq listing matters.
Turnstone later discontinued TIDAL-01 clinical studies and halted further program development while reviewing strategic alternatives. Subsequent corporate-status disclosures documented an acquisition-related transition, Nasdaq delisting, and termination of Exchange Act registration for its common stock.
Summary not available.